Inhibition of gastric emptying in response to intestinal lipid is dependent on chylomicron formation.
Lipid in the intestine initiates feedback inhibition of proximal gastrointestinal function and food intake. In rats and humans, inhibition of gastric emptying is mediated, at least in part, by cholecystokinin (CCK)-A receptors, and in rats there is evidence for involvement of an intestinal vagal afferent pathway. The mechanism by which luminal lipid acts to release CCK or activate vagal afferent nerve terminals is unclear. The role of chylomicron formation in this sensory transduction pathway has been investigated using the hydrophobic surfactant Pluronic L-81 that inhibits chylomicron formation. Gastric emptying of liquids was measured in awake rats fitted with a Thomas gastric fistula and a duodenal cannula. Intestinal perfusion of lipid induced a dose-dependent inhibition of gastric emptying (6, 12, and 39% inhibition for 25, 50, and 100 mg lipid, respectively). Perfusion of lipid with Pluronic L-81 (2.8% wt/vol) reversed the lipid-induced inhibition of gastric emptying. Pluronic L-63, a chemically similar surfactant that has no effect on chylomicron formation, had no effect on lipid-induced inhibition of gastric emptying. Perfusion of the intestine with lipid (100 mg) increased plasma levels of CCK from 1.9 +/- 0.8 to 6. 5 +/- 1 pM. This increase was blocked by Pluronic L-81 but unaffected by L-63. These results provide evidence that chylomicron formation is important in the signaling of lipid in the intestinal lumen to CCK endocrine cells and to producing feedback inhibition of gastric emptying.
Raybould
H E
HE
Center for Ulcer Research and Education/Digestive Diseases Research Center, Department of Physiology, University of California Los Angeles School of Medicine, Los Angeles, CA 90073, USA.
Meyer
J H
JH
Tabrizi
Y
Y
Liddle
R A
RA
Tso
P
P
D000818:Animals; D002914:Chylomicrons / Q000378:metabolism*; D005246:Feedback / Q000187:drug effects / Q000502:physiology; D005746:Gastric Emptying / Q000187:drug effects* / Q000502:physiology; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D007422:Intestines; D008055:Lipids / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley
D002914:Chylomicrons; D000960:Hypolipidemic Agents; D008055:Lipids